Harvard Management Company’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Harvard Management Company’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-128,119	Closed	-$679K	–	20
2019 Q3	$679K	Hold	128,119	–	–	0.06%	17
2019 Q2	$987K	Hold	128,119	–	–	0.24%	16
2019 Q1	$2.55M	Hold	128,119	–	–	0.65%	14
2018 Q4	$1.69M	Hold	128,119	–	–	0.36%	16
2018 Q3	$4.71M	Hold	128,119	–	–	1.2%	15
2018 Q2	$4.48M	Sell	128,119 -166,770	-57%	-$6.39M	1.06%	15
2018 Q1	$13.7M	Sell	294,889 -539,601	-65%	-$19.7M	1.68%	8
2017 Q4	$31.3M	Sell	834,490 -469,130	-36%	-$20.5M	27.41%	1
2017 Q3	$69.4M	Buy	+1,303,620	New	+$77.5M	6.83%	2

Other funds holding KDNY

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harvard Management Company's KDNY Position: Q4 2019 in Review

Harvard Management Company sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2019, closing a stake of 128,119 shares — an estimated $679K sold.

Harvard Management Company first reported a position in KDNY in Q3 2017 and held it in 9 quarters. The position peaked at $69.4M in Q3 2017. 84 funds tracked by Wall St. Rank hold KDNY as of Q4 2019.

Harvard Management Company reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Harvard Management Company sold 128,119 Chinook Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $679K.
Harvard Management Company first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2017 and held it in 9 quarters.
Harvard Management Company's Chinook Therapeutics, Inc. Common Stock position peaked at $69.4M in Q3 2017.
84 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Harvard Management Company's 13F filing for Q4 2019, filed 14 Feb 2020.